TrialEBioMedicine2020

Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study.

Tatsuro Fukuhara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.